Can I Take Folate With Repatha (Evolocumab)?

How Repatha (Evolocumab) Works in the Body

Evolocumab is a fully human monoclonal IgG2 antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9) with high affinity, preventing PCSK9 from tagging LDL receptors for degradation. With more LDL receptors recycled to the hepatocyte surface, LDL-C clearance rises sharply.

Pharmacokinetic Profile

Monoclonal antibodies are not processed by cytochrome P450 enzymes. Evolocumab is catabolized by ubiquitous proteolytic pathways into amino acids, the same route used to break down any dietary protein. This distinction is clinically significant: most supplement-drug interactions happen at CYP3A4, CYP2C9, P-glycoprotein, or organic anion transporter sites. None of those sites are relevant to evolocumab. The FDA prescribing information for Repatha lists no drug-drug interactions of clinical significance, and no supplement-specific warnings appear in the labeling [1].

Clinical Efficacy Data

In the FOURIER cardiovascular outcomes trial (N=27,564 patients with established ASCVD on optimized statin therapy), evolocumab at 140 mg every 2 weeks or 420 mg monthly reduced LDL-C by a mean of 59% compared with placebo, reaching a median on-treatment LDL-C of 30 mg/dL [2]. Major adverse cardiovascular events (MACE) fell by 15% over a median 2.2-year follow-up (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) [2]. These outcomes depend on consistent drug exposure, which folate supplementation does not disrupt.

What Folate Does and Why Cardiac Patients Take It

Folate (vitamin B9) is a water-soluble B vitamin essential for DNA synthesis, red blood cell formation, and the remethylation of homocysteine to methionine. The body requires the active metabolite 5-methyltetrahydrofolate (5-MTHF) to drive that remethylation reaction, with vitamin B12 as a cofactor.

The Homocysteine Connection

Elevated plasma homocysteine is associated with increased cardiovascular risk independent of LDL-C [3]. A 2010 Cochrane review of 25 randomized trials found that folic acid supplementation reduces plasma homocysteine concentrations by approximately 25% from baseline, with larger reductions in people who start with higher homocysteine levels [4]. That number has been reproduced across populations. Whether homocysteine lowering itself reduces cardiovascular events remains debated, but the intervention is low-cost and carries minimal risk.

MTHFR Polymorphisms and Folate Need

Roughly 10 to 15% of people of Northern European descent carry two copies of the MTHFR C677T variant, which reduces enzyme activity by up to 70% and predisposes carriers to higher homocysteine levels [5]. Patients on Repatha for familial hypercholesterolemia (FH) may also carry MTHFR variants at similar population rates. For those individuals, supplemental folate, often as 5-MTHF rather than folic acid, is a reasonable adjunct to address a separate metabolic gap that a PCSK9 inhibitor cannot fill.

Folate and Anticonvulsant Use

Some patients on long-term phenytoin, carbamazepine, or valproate alongside a lipid-lowering regimen may need supplemental folate because these drugs deplete folate stores. If you take an anticonvulsant and Repatha together, discuss folate supplementation with your neurologist; the interaction concern is anticonvulsant-folate, not evolocumab-folate.

Is There Any Pharmacological Conflict Between Folate and Evolocumab?

No. The short answer is worth stating plainly before the explanation.

Pharmacokinetic Analysis

Folate is absorbed in the proximal small intestine via the proton-coupled folate transporter (PCFT/SLC46A1) and the reduced folate carrier (RFC). Evolocumab is administered subcutaneously and bypasses intestinal absorption entirely, distributing via the lymphatics into systemic circulation. The two substances never compete for the same transporter, enzyme, or receptor. Plasma protein binding, volume of distribution, and elimination half-life are mechanistically independent between them.

Pharmacodynamic Analysis

Evolocumab acts exclusively on the PCSK9-LDL receptor axis in hepatocytes. Folate acts on one-carbon metabolism, homocysteine remethylation, and nucleotide synthesis. These pathways do not share rate-limiting steps or regulatory crossover that would cause one to antagonize or amplify the other. No published pharmacodynamic study has identified additive toxicity, antagonism, or unexpected combination between PCSK9 inhibitors and B vitamins. A 2021 review of PCSK9 inhibitor drug interactions published in the European Journal of Clinical Pharmacology confirmed no biologically plausible interaction with folate, B12, or B6 [6].

What the Guidelines Say

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction does not list folate or B vitamins as contraindicated, cautioned, or requiring monitoring alongside PCSK9 inhibitors [7]. The 2021 ESC/EAS Guidelines for the Management of Dyslipidaemias similarly contain no folate-related restriction for evolocumab [8].

Who Should Consider Taking Folate Alongside Repatha?

Not every Repatha patient needs folate supplementation. The people most likely to benefit include those in specific clinical scenarios.

Patients With Elevated Homocysteine

A fasting plasma homocysteine above 15 micromoles per liter is classified as hyperhomocysteinemia. If your cardiologist or lipidologist checks this marker and finds it elevated, folate 400 to 1,000 mcg daily (or 5-MTHF 400 to 1,000 mcg daily for MTHFR carriers) is a standard adjunctive approach [3]. Your Repatha dose does not need adjustment when adding folate.

Patients With Familial Hypercholesterolemia Planning Pregnancy

Homozygous or heterozygous FH patients using evolocumab who are planning pregnancy face a complex clinical picture: Repatha's safety in pregnancy has not been established, and clinicians often discontinue it before conception. Adequate folate intake is essential for neural tube defect prevention, and the standard recommendation of 400 to 800 mcg daily beginning at least one month before conception applies regardless of a prior history of PCSK9 inhibitor use [9].

Patients on Concomitant Metformin

Metformin reduces intestinal folate absorption over time, and many patients with metabolic syndrome or type 2 diabetes take metformin alongside a statin or PCSK9 inhibitor. For those individuals, monitoring homocysteine and folate levels every 12 months is a reasonable practice. Adding a B-complex supplement with 400 to 800 mcg folic acid costs little and addresses the metformin-driven depletion without any concern about evolocumab interaction.

Practical Dosing and Timing

Because no interaction exists, no special timing is required. Folate supplements can be taken at any time relative to Repatha injections. The following table summarizes common supplementation scenarios.

| Scenario | Folate Form | Typical Dose | Notes | |---|---|---|---| | General cardiovascular health | Folic acid | 400 mcg/day | Standard dietary reference intake for adults | | MTHFR C677T homozygous | 5-MTHF | 400 to 1,000 mcg/day | Bypasses impaired MTHFR conversion | | Elevated homocysteine (>15 umol/L) | Folic acid or 5-MTHF | 800 to 5,000 mcg/day | Add B12 400 to 1,000 mcg and B6 25 to 50 mg | | Anticonvulsant-induced depletion | Folic acid | 1,000 to 5,000 mcg/day | Supervised by neurologist | | Pre-conception or pregnancy | Folic acid | 400 to 800 mcg/day | Begin 1 month before conception per ACOG [9] |

Repatha injection timing (every 2 weeks for 140 mg, monthly for 420 mg) is independent of any oral supplement schedule.

Monitoring Recommendations When Taking Both

Routine lipid panels remain the standard monitoring tool for evolocumab therapy. The ACC recommends checking fasting lipids 4 to 12 weeks after initiating or adjusting PCSK9 inhibitor therapy and then every 3 to 12 months thereafter [7].

Additional Labs to Request

If you are taking folate for a clinical reason, ask your prescriber to add the following to your next metabolic panel:

• Serum folate (target: above 4 ng/mL)
• Plasma homocysteine (target: below 10 micromoles per liter for cardiovascular risk reduction)
• Serum B12 (target: above 300 pg/mL; folate supplementation without B12 can mask B12 deficiency)
• CBC with differential (to screen for megaloblastic anemia, particularly if B12 deficiency is suspected)

None of these markers need to be tracked differently because of evolocumab. The PCSK9 inhibitor does not alter folate metabolism or B12 absorption.

When to Tell Your Prescriber

Tell your prescriber about any supplement you start, including folate. The reason is documentation, not drug safety. Knowing you take folate ensures that a rising or falling homocysteine on your panel is interpreted in context. It also helps the clinical team accurately attribute any lab abnormality.

Understanding the Broader Supplement Field for Repatha Patients

Folate stands out as one of the safer supplements a Repatha patient can take. For perspective, some other common supplements carry more meaningful considerations alongside evolocumab or its underlying conditions.

Red Yeast Rice and Statins Already On Board

Many Repatha patients also take a statin. Red yeast rice contains monacolin K, a compound chemically identical to lovastatin. Adding red yeast rice to statin therapy raises myopathy risk, and this risk is independent of evolocumab. The FDA has warned that red yeast rice products containing meaningful amounts of monacolin K are effectively unapproved drugs [10]. Folate carries none of this concern.

High-Dose Fish Oil

Prescription omega-3 fatty acids (icosapentaenoic acid, as in icosapentaenoic acid ethyl ester, brand name Vascepa) are sometimes prescribed alongside PCSK9 inhibitors for residual triglyceride risk. Over-the-counter fish oil at doses above 3 grams daily may modestly increase bleeding risk, particularly in patients also on antiplatelet agents. Folate has no pro-bleeding mechanism.

Supplements With Genuine Caution Flags

St. John's Wort induces CYP3A4 and P-glycoprotein, which matters for small-molecule drugs, though its relevance to a monoclonal antibody like evolocumab is theoretical at best. Regardless, it is worth avoiding in the setting of complex cardiovascular regimens. Niacin at pharmacologic doses (1,500 to 3,000 mg) can cause flushing and may modestly raise uric acid and glucose; it adds no benefit over statin plus PCSK9 inhibitor therapy per the AIM-HIGH trial (N=3,414) [11]. Folate appears on neither of these concern lists.

Clinical Framework for Supplement Decisions With Repatha

The following three-question decision framework may help patients and clinicians triage supplement safety questions alongside evolocumab:

Step 1: Does the supplement alter CYP450 enzymes, P-glycoprotein, or organic anion transporters? If yes, investigate further. If no (as with folate), pharmacokinetic conflict is highly unlikely.

Step 2: Does the supplement share a biological target or downstream pathway with the drug? Evolocumab targets PCSK9/LDL receptor recycling. Folate targets one-carbon metabolism. No shared pathway, no pharmacodynamic conflict.

Step 3: Does the supplement address a genuine clinical gap the drug cannot fill? Evolocumab does not lower homocysteine. For patients with MTHFR variants or elevated homocysteine, folate fills a real gap that no PCSK9 inhibitor addresses. Adding it is rational, not redundant.

Applying this framework, folate clears all three steps without a single concern flag. Supplements that fail Step 1 or Step 2 warrant prescriber discussion before use.

Key Takeaways for Patients on Repatha Considering Folate

Folate is a water-soluble B vitamin. Repatha is a subcutaneously injected monoclonal antibody. These two are metabolized through entirely different systems and act on entirely different biological targets. No dose separation is needed. No monitoring adjustment to your Repatha protocol is required because of folate.

Start with a standard 400 mcg daily dose unless your clinician has identified MTHFR variants, elevated homocysteine above 15 micromoles per liter, anticonvulsant use, or metformin-driven depletion, any of which may justify a higher therapeutic dose or 5-MTHF formulation.

Tell your prescriber you are supplementing. Request a baseline homocysteine and B12 level so that future lab trends are interpretable. Your next lipid panel, due 4 to 12 weeks after any Repatha dose adjustment per ACC guidance, should show LDL-C well below 70 mg/dL (or below 55 mg/dL if you have established ASCVD and your clinician follows the more aggressive ESC/EAS target) [7, 8]. Folate will not interfere with reaching that target.